Effects of Curcumin on Inflammation and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

The study will be a randomised, double blinded, placebo controlled design.It will include 2 groups : trial group and placebo groupPatients in both groups are children on regular hemodialysisThe patients in the trial group will receive Curcumin capsule 1 gm for 3 months , and the placebo group will receive a placebo capsule for 3 monthsAll patients will be evaluated clinically, and laboratory at baseline, at 3 months after end of supplementation.

Inclusion Criteria:Male or female pediatric patients with weight of at least 30 kilograms.Undergoing regular hemodialysis for at least 6 months.Exclusion Criteria:Bleeding disorders.Chronic liver disease.Diabetes mellitus.Autoimmune diseases.Receiving drugs that are contraindicated, or have major interactions with curcumin, and can't be discontinued or replaced.Receiving corticosteroids, or immune-suppressants.Patients taking any antioxidant supplements including vitamin E, ascorbic acid, omega -3 fatty acid, or L-carnitine within 3 months prior to enrollment in our study.